Development of a Novel Anti-CD19 Antibody-Drug Conjugate
B-cell lymphoma is a cancer in need of a therapy. Patients with B-cell lymphoma often respond to first line therapies, but tumor recurrence rate is high and prognosis often poor. Novel approaches to B-cell lymphoma treatment are needed.
CD19 is a B-cell transmembrane glycoprotein that plays a key role in B-cell malignancies and autoimmune diseases and is a target of interest for new B-cell lymphoma therapies. Of the anti-CD19 therapies in development and/or clinical trials, antibody-drug conjugates (ADCs) are some of the most promising, as they are both specific and toxic. In the ADC mechanism of action, the antibody binds CD19 on the B-cell surface stimulating internalization of the antibody-receptor complex. Upon internalization toxin is released, killing the tumor cell.
In this work, Li et al. created a novel CD19-binding monoclonal antibody, RC58 . They used pHAb Amine Reactive dyes to analyze internalization of the RC58 antibody.
Details of their work can be found in this 2018 International Immunopharmacology paper: "Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment".